Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DA-020 · 1 trial · 2 indications
Amount of hair loss during chemotherapy treatment measured by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0. The Common Terminology Criteria for Adverse Events is a common terminology developed by the National Cancer Institute to describe and grade adverse events related to cancer therapy.
| Arm | Type | Description |
|---|---|---|
| DA-020 | ACTIVE_COMPARATOR | Topical DA-020 Solution |
| Placebo | PLACEBO_COMPARATOR | Topical Placebo Solution |
| DA-020 and Hyperforin (1.5%) | ACTIVE_COMPARATOR | DA-020 and Hyperforin (1.5%) |
| Name | Type | Description |
|---|---|---|
| DA-020 | DRUG | 7mL application of DA-020 (Topical Oxymetazoline) |
| Placebo | DRUG | Topical placebo solution |
| DA-020 and Hyperforin | DRUG | 7mL application of DA-020 (Topical Oxymetazoline) and Hyperforin (1.5%) |
Inclusion Criteria: * Diagnosed with stage I or stage II breast cancer * Scheduled but not begun, at least 4 cycles of taxane and/or anthracycline-based chemotherapy. * Ages 18-65 * Able to give informed consent Exclusion Criteria: * Resting blood pressure outside the range of 105-140/ 55-99 * Un...
DA-020 is an investigational small molecule being developed for the treatment of chemotherapy induced alopecia, a condition of hair loss caused by chemotherapy. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
DA-020 is being developed by Applied Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol APLT. The company is conducting clinical trials to evaluate the safety and efficacy of DA-020 for chemotherapy induced alopecia.
DA-020 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety and tolerability.
DA-020 is being studied in a Phase 1 clinical trial with the identifier NCT07397325, titled 'Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia'. This randomized, double-blind, placebo-controlled trial is recruiting 60 female participants aged 18 years and older in Brazil and Italy.
Yes, the current Phase 1 clinical trial of DA-020 is enrolling only female participants. The trial is studying the drug for chemotherapy induced alopecia, a condition that commonly affects women undergoing chemotherapy, and is being conducted at sites in Brazil and Italy.